Replies to post #3282 on COSCIENS Biopharma Inc (CSCI)

[kei]

~ i agree! :)

[BERKSHIRE AGENT]

OMG look at this.....Macimorelin Acetate (AEZS-130)~Aeterna Zentaris owns the worldwide rights to this novel patented compound.

AEZS has a significant amount of drugs in the pipeline that are entering the Phase 3 approval. The First is the Catalyst Cancer Drug which can hit any time. About Macimorelin Acetate (AEZS-130) Macimorelin acetate, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. The Company has completed a Phase 3 trial for use in evaluating AGHD, and has submitted a NDA to the FDA in this indication. Macimorelin acetate has been granted orphan drug designation by the FDA for use in AGHD. Furthermore, macimorelin acetate is in a Phase 2 trial as a treatment for cancer-induced cachexia. Aeterna Zentaris owns the worldwide rights to this novel patented compound.